<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386813</url>
  </required_header>
  <id_info>
    <org_study_id>2013-03-071</org_study_id>
    <nct_id>NCT02386813</nct_id>
  </id_info>
  <brief_title>International Extranodal NK/T-cell Lymphoma Project</brief_title>
  <acronym>PINK</acronym>
  <official_title>International Extranodal NK/T-cell Lymphoma Project: Prognostic Factors in the Era of Nonanthracycline-based Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seok Jin Kim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consortium for Improving Survival of Lymphoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asia Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dok Hyun Yoon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arnaud Jaccard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wee Joo Chng</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soon Thye Lim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huangming Hong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yong Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kian Meng Chang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yoshinobu Maeda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fumihiro Ishida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-Yeop Shin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jin Seok Kim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seong Hyun Jeong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deok-Hwan Yang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jae-Cheol Jo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gyeong-Won Lee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chul Won Choi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Won-Sik Lee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tsai-Yun Chen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kiyeun Kim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sin-Ho Jung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tohru Murayama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yasuhiro Oki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ranjana Advani</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Francesco dâ€™Amore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norbert Schmitz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cheolwon Suh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ritsuro Suzuki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yok Lam Kwong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tong-Yu Lin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to explore risk factors for poor progression-free survival (PFS) and overall
      survival (OS) in ENKTL, and establish a prognostic model for ENKTL patients treated with
      non-anthracycline based treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective cohort study using anonymized information from patients with ENKTL.
      The following criteria are required: (1) Patients diagnosed with ENKTL, nasal type between
      January 1, 1995 and December 31, 2014; (2) Patients treated with non-anthracycline based
      therapy as an initial treatment. The pathology of initial diagnosis was reviewed by
      designated pathologists.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>Time between the date of diagnosis and any kinds of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 year</time_frame>
    <description>Time between the date of diagnosis and any kinds of death or relapse/progression</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">770</enrollment>
  <condition>Extranodal NK/T-cell Lymphoma, Nasal Type</condition>
  <arm_group>
    <arm_group_label>Training cohort</arm_group_label>
    <description>Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013;
Patients treated with non-anthracycline based therapy as an initial treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
    <description>Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014;
Patients treated with non-anthracycline based therapy as an initial treatment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31,
             2014;

          2. Patients treated with non-anthracycline based therapy as an initial treatment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with ENKTL, nasal type

          -  Patients diagnosed between January 1, 1995 and December 31, 2014

          -  Patients treated with nonanthracycline-based therapy as the initial treatment after
             diagnosis

          -  Nonanthracycline-based therapy includes the following treatments:

          -  Radiotherapy including concurrent chemoradiation

          -  Chemotherapy not including anthracycline such as doxorubicin (e.g. SMILE, VIPD) The
             type of salvage treatment will not be a criterion for exclusion. Thus, patients who
             had received various kinds of salvage treatment including anthracycline-containing
             regimens can be included. Patients who had undergone autologous or allogeneic stem
             cell transplantation can also be included in the analysis if they satisfy the
             above-mentioned inclusion criteria.

        Exclusion Criteria:

          -  Patients who had received anthracycline-based therapy, such as CHOP or CHOP-like
             regimens, as the initial treatment.

          -  Patients who do not have pathology slides available for central review.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Seog Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>April 8, 2017</last_update_submitted>
  <last_update_submitted_qc>April 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Seog Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

